• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    2/9/24 9:03:02 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 ENVISTA HOLDINGS CORPORATION COMMON STOCK Cusip #29415F104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #29415F104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 801,492 Item 6: 0 Item 7: 811,559 Item 8: 0 Item 9: 811,559 Item 11: 0.472% Item 12: HC Cusip #29415F104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 811,559 Item 8: 0 Item 9: 811,559 Item 11: 0.472% Item 12: IN Item 1(a). Name of Issuer: ENVISTA HOLDINGS CORPORATION Item 1(b). Address of Issuer's Principal Executive Offices: 200 S Kraemer Blvd, Bldg E Brea, CA 92821 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 29415F104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 811,559 (b) Percent of Class: 0.472% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 811,559 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ENVISTA HOLDINGS CORPORATION. No one other person's interest in the COMMON STOCK of ENVISTA HOLDINGS CORPORATION is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Diversifying Solutions LLC IA Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ENVISTA HOLDINGS CORPORATION at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $NVST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    4/26/2024$33.00 → $21.00Overweight → Equal-Weight
    Morgan Stanley
    2/26/2024$19.00Underperform
    Leerink Partners
    2/9/2024$30.00 → $23.00Buy → Hold
    Jefferies
    More analyst ratings

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Keel Paul A covered exercise/tax liability with 12,787 shares, decreasing direct ownership by 3% to 401,652 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      5/27/25 4:45:59 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Chief Accounting Officer Kaabi Faez C covered exercise/tax liability with 4,319 shares and was granted 9,685 shares, increasing direct ownership by 12% to 49,996 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      2/27/25 5:27:45 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SVP, Strategy & Bus. Dev. Reis Mischa covered exercise/tax liability with 3,813 shares and was granted 8,475 shares, increasing direct ownership by 11% to 47,382 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      2/27/25 5:27:34 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    SEC Filings

    See more
    • SEC Form SD filed by Envista Holdings Corporation

      SD - Envista Holdings Corp (0001757073) (Filer)

      5/30/25 4:39:21 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings Corporation

      SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)

      5/15/25 4:27:38 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Envista Holdings Corporation

      10-Q - Envista Holdings Corp (0001757073) (Filer)

      5/1/25 4:17:13 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Compass Diversified Announces Stephen Keller as Chief Financial Officer

      WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

      8/26/24 6:00:00 AM ET
      $AVY
      $CODI
      $NVST
      Containers/Packaging
      Consumer Discretionary
      Home Furnishings
      Medical/Dental Instruments
    • Envista Holdings Corporation Announces Key Leadership Appointments

      BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an

      7/15/24 4:10:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Envista Holdings Corporation

      SC 13G - Envista Holdings Corp (0001757073) (Subject)

      11/8/24 12:09:03 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

      SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

      2/15/24 10:19:33 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Envista Holdings Corporation

      SC 13G - Envista Holdings Corp (0001757073) (Subject)

      2/14/24 4:08:38 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Financials

    Live finance-specific insights

    See more
    • Envista Reports First Quarter 2025 Results

      BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

      5/1/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Schedules First Quarter 2025 Earnings Call

      BREA, Calif., April 8, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2025 on Thursday, May 1, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You ca

      4/8/25 4:15:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Reports Fourth Quarter 2024 Results

      BREA, Calif., Feb. 5, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2024. "In Q4 2024, Envista delivered results that were in line with expectations, indicating that our focus on growth, operations, and people is having a positive impact," said Paul Keel, Envista's CEO.  "2024 was a transition year for our company.  After a challenging first half, we took actions over the last two quarters to position ourselves for improved performance moving forward.  While we still have much more to do, we're encourag

      2/5/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Envista upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00

      5/27/25 9:05:49 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Envista with a new price target

      Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00

      12/4/24 7:46:09 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously

      10/31/24 6:27:39 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/14/24 4:40:20 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/13/24 6:01:10 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      11/20/23 5:49:32 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Envista Announces Participation in Stifel 2025 Jaws & Paws Conference

      BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET. A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/.  ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS

      5/22/25 4:15:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Hitachi Digital Services Announces Five-Year Strategic IT Partnership with Envista

      DALLAS, May 15, 2025 /PRNewswire/ -- Hitachi Digital Services, the digital consultancy and technology services subsidiary of Hitachi, Ltd. (TSE: 6501), today announced a five-year agreement with Envista Holdings Corporation (NYSE:NVST) ("Envista"), a global leader in dental care, to deliver end-to-end IT managed services across Envista's operations in more than 60 countries. Following a highly competitive tendering process, Envista selected Hitachi Digital Services as its strategic IT partner to support its digital transformation and operational efficiency goals. Under this ag

      5/15/25 11:23:00 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Reports First Quarter 2025 Results

      BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

      5/1/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care